Scarica l'app Stockscreener
94.45
4.07%
-4.01
Dopo l'orario di chiusura:
94.77
0.32
+0.34%
Kodiak Sciences Inc Borsa (KOD) Ultime notizie
Kodiak Sciences More Than Doubles on Eye Disease Trial Results - Barchart.com
Why is Kodiak Sciences stock rallying today? - Investing.com
Form 13D/A Kodiak Sciences Inc. For: 1 October By Investing.com - Investing.com Nigeria
Kodiak Sciences stock clears a major clinical hurdle - AD HOC NEWS
Kodiak Sciences(KOD.US) 10% Shareholder Buys US$156.99 Million in Common Stock - Moomoo
A stock acquisition changes beneficial ownership by more than 1% at Kodiak Sciences (KOD). - Stock Titan
Baker Bros. Advisors Reports Multiple Open-Market Buys of Kodiak Sciences Stock - Kalkine Media
In 30 transactions, Baker funds bought shares of Kodiak Sciences (KOD). - Stock Titan
Kodiak Sciences Inc. (KOD) Stock Price, News, Quote & History - Yahoo! Finance Canada
A $32 Biotech Became a $90 Biotech Overnight. Is It Too Late to Buy Kodiak? - 24/7 Wall St.
H.C. Wainwright Maintains Kodiak Sciences(KOD.US) With Buy Rating, Maintains Target Price $96 - Moomoo
Goldman Sachs Maintains Kodiak Sciences(KOD.US) With Hold Rating, Announces Target Price $103 - Moomoo
EBITDA margin % of Kodiak Sciences, Inc. – HAN:K27 - TradingView
Form 4 Kodiak Sciences Inc For: 29 September By Investing.com - Investing.com Australia
KOD Stock Soars 178% on Positive Wet AMD Data as BLA Filing Nears - TradingView
Kodiak Sciences (KOD) Surges 138% in September Amid Strong Insider Buying and High Price-to-Sales Ratio - GuruFocus
H.C. Wainwright raises Kodiak Sciences stock price target on trial data - Investing.com Nigeria
Results are due Monday from a study of two potential treatments for an age-related eye disease. - Stock Titan
Biotech Stock Kodiak Sciences (Nasdaq: KOD) Leads Nasdaq's Monday Gainers; up 177% - Investorideas.com
Why Did KOD, RGEN, BIIB Stocks Rise To 52-Week Highs? - TradingView
New Eye Treatment Boosts Kodiak Into Ranks of Resurgent Biotechs - Yahoo Finance
KODIAK SCIENCES INC. : H.C. WAINWRIGHT RAISES TARGET PRICE TO $96 FROM $58 - webull.com
Why Kodiak Sciences Skyrocketed Today - theglobeandmail.com
KOD Stock Cracks September’s Top 5 Biotech Gainers On Eye Drug Win — But ‘Pharma Bro’ Shkreli Says It ‘Still Sucks’ - Yahoo Finance
MDB, KOD, NVTS, BA, NVDA: 5 Trending Stocks TodayNVIDIA (NASDAQ:NVDA) - Benzinga
Kodiak Sciences (KOD) Climbs Nearly 3x on Promising Wet AMD Trial - Yahoo Finance
Kodiak Sciences (KOD) Rockets As Phase 3 Catalysts Loom - StocksToTrade
Kodiak Sciences KOD Stock Soars Toward $100 After Strong Phase 3 DAYBREAK Trial Data - FXLeaders
Kodiak Stock Gains 183% as New Eye Drugs Take Aim at Regeneron’s Eylea - Barron's
KOD Stock Explodes As Phase 3 Countdown Draws Wall Street Firepower - StocksToTrade
KOD Stock Explodes As Phase 3 Catalyst Frenzy Draws Wall Street - timothysykes.com
Kodiak Stock Soars (Again) As Data Shows Long-Lasting Eye Meds Are The 'Real Deal' (KOD) - Seeking Alpha
Jefferies cuts Kodiak Sciences stock price target on valuation review By Investing.com - Investing.com Nigeria
Jefferies cuts Kodiak Sciences stock price target on valuation review - Investing.com
Kodiak Sciences, AMC Entertainment, Agenus And Other Big Stocks Moving Higher On Monday - Benzinga
Kodiak Sciences (KOD) Surges 156% After Positive Phase 3 DAYBREA - GuruFocus
KOD Maintained by HC Wainwright & Co. -- Price Target Raised to $96 - GuruFocus
12 Health Care Stocks Moving In Monday's Intraday Session - Benzinga
Kodiak Sciences soars as Zenkuda, tabirafusp-ted hit primary endpoints in phase III wet AMD trial - Yahoo Finance
KOD Stock Explodes As Phase 3 Catalyst Frenzy Hits - timothysykes.com
Kodiak Sciences Inc. (KOD) Discusses DAYBREAK Topline Data and Primary Endpoint ResultsSlideshow - Seeking Alpha
Kodiak skyrockets on positive study data for 2 eye drugs - BioPharma Dive
Kodiak Sciences (KOD) Shares Soar 145% on Positive Phase 3 Trial Results for Zenkuda - GuruFocus
Kodiak Sciences options flow after positive Phase 3 DAYBREAK AMD trial data - Investing.com
Kodiak’s stock rallies on Phase III wAMD success - Yahoo Finance
AMD phase III docks at Kodiak treasure island - BioWorld News
Kodiak Sciences (KOD) Soars on Positive Phase 3 DAYBREAK Study Results - GuruFocus
Kodiak Sciences Soars 141% on “Truly Impressive” Pivotal Wet AMD Trial Win - TIKR.com
Kodiak Sciences skyrockets as Zenkuda, tabirafusp excel in late-stage wet AMD trial - Seeking Alpha
Why Is Regeneron Pharmaceuticals Stock Falling Today?Regeneron Pharmaceuticals (NASDAQ:REGN), Kodiak S - Benzinga
New Real-Time Market Updates on YouTube Spotlight Kodiak Sciences Inc (KOD) - GuruFocus
Kodiak Sciences' Zenkuda Therapy Achieves Breakthrough in Vision Improvement - Intellectia AI
Kodiak Sciences soars after pivotal DAYBREAK Phase 3 wet AMD results clear key endpoints - Quiver Quantitative
This Biotech Company Added Nearly $3B To Its Market Cap – Here’s Why KOD Stock Is Ripping Today - Yahoo Finance
Kodiak Sciences Says Eye Drug on Par with Regeneron's Medicine - Benzinga
Kodiak Sciences stock hits 52-week high at 61.28 USD - Investing.com
Kodiak Sciences stock hits 52-week high at 61.28 USD By Investing.com - Investing.com Nigeria
Kodiak Sciences Stock Surges 125% After Late-Stage Drug Trial Success - Yahoo Finance
Form 8K Kodiak Sciences Inc For: 28 September By Investing.com - Investing.com South Africa
Kodiak Sciences posts positive Phase 3 DAYBREAK eye results - TipRanks
KOD Stock Jumps As Phase 3 Retina Catalysts Approach - timothysykes.com
KOD Stock Jumps As Traders Position For Phase 3 Data Wave - StocksToTrade
Kodiak Sciences Inc stock Analysis: Daily Trend and Major Catalyst Impact - The Cryptonomist
Kodiak Sciences: Zenkuda and tabirafusp-ted meet primary endpoints in Phase 3 DAYBREAK - TradingView
Kodiak Sciences stock soars on positive AMD trial data - Investing.com
Both treatments met a year-one vision goal in Kodiak Sciences (KOD)'s eye disease trial. - Stock Titan
KOD Stock Jumps As Phase 3 Catalysts Draw Wall Street Targets - StocksToTrade
Why Is Kodiak Sciences (NASDAQ:KOD) Suddenly a Must-Watch Healthcare Stocks Name? - Kalkine Media
Kodiak Sciences Inc. Announces Zenkuda and Tabirafusp-Ted Meet Primary Endpoints in Phase 3 Daybreak Study in Patients with Wet Age-Related Macular Degeneration - marketscreener.com
12 Health Care Stocks Moving In Monday's Pre-Market Session - Benzinga
KOD Stock Jumps As Phase 3 Data Catalyst Looms - timothysykes.com
KOD Stock Jumps As Phase 3 Catalysts And Analyst Targets Align - StocksToTrade
Kodiak’s Zenkuda meets primary endpoint in wet AMD trial - Investing.com
Kodiak Reports Zenkuda Phase 3 Wet AMD Results - grafa.com
Kodiak Sciences Shares Rise After DAYBREAK Phase 3 Trial Results - Yahoo Finance
0.05%
0.82%
Apri su Yahoo
|
Apri su Google
|
Aperto in Finviz
|
Apri in MarketWatch
|
Aperto a EDGAR
|
Aperto su Reuters
Capitalizzazione:
|
Volume (24 ore):